Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Trial Profile

A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Remetinostat (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors TetraLogic Pharmaceuticals
  • Most Recent Events

    • 25 Jul 2018 According to a Medivir AB media release, data were presented at the International Investigative Dermatology (IID) meeting
    • 18 May 2018 According to a Medivir AB media release, data from this study will be presented at the International Investigative Dermatology (IID) meeting on 19th May 2018.
    • 13 Oct 2017 According to a Medivir AB media release, data were presented as an abstract at the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force meeting October 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top